This work was supported by the Joint Project &#8220;The use of plants for the production of an autoimmune diabetes edible vaccine (eDIVA)&#8221; (Project ID: 891854) funded by the University of Verona in the framework of the call 2014.

1. Red beet and spinach cultivation
<ol>
	<li>Grow red beet (B. vulgaris cv Moulin Rouge) and spinach (S. oleracea cv Industria) plants in a growth chamber, using 150 &#181;E of light intensity, 65% relative humidity, 12 h light/dark cycle at 23/21 &#176;C, respectively.</li>
	<li>After seed germination, fertilize the plants twice a week with a 1 g/L solution of a commercially available fertilizer (Table of Materials). For agroinfiltration use five-week-old spinach and six-week-old red beet plants.</li>
</ol>
2. Transient expression through the deconstructed plant virus-based technology
<ol>
	<li>Construction of plant expression vectors
	<ol>
		<li>Introduce the vectors - the 5&#8217; module (pICH20111), the 3&#8217; modules (pICH31070.GAD65mut, pICH31070.&#8710;87G65mut and pICH7410.eGFP), prepared as previously described1,2,7, and the integrase module (pICH14011) - in Agrobacterium tumefaciens GV3101 strain using standard techniques. Grow on LB medium containing 50 &#956;g/mL rifampicin and appropriate vector-specific antibiotics (50 &#956;g/mL carbenicillin for pICH20111, pICH14011 and pICH7410.eGFP, 50 &#956;g/mL kanamycin for pICH31070) for 2 days at 28 &#176;C.</li>
		<li>Screen the colonies by colony PCR using the following specific primers for each vector: 5&#8217;-ATCTAAGCTAGGGTACCTCG-3&#8217; and 5&#8217;-ACACCGTAAGTCTATCTCTTC-3&#8217; for both the 3&#8217; modules pICH31070.GAD65mut and pICH31070.&#8710;87G65mut, with an annealing temperature of 55 &#176;C and an elongation time of 110 s, 5&#8217;-TGAAGTTCATCTGCACCAC-3&#8217; and 5&#8217;-ACACCGTAAGTCTATCTCTTC-3&#8217; for the third 3&#8217; module pICH7410.eGFP, with an annealing temperature of 53 &#176;C and an elongation time of 30 s, 5&#8217;-AATGTCGATAGTCTCGTACG-3&#8217; and 5&#8217;-TCCACCTTTAACGAAGTCTG-3&#8217; for the 5&#8217; module, with an annealing temperature of 53 &#176;C and an elongation time of 20 s and 5&#8217;-GGCAACCGTTATGCGAATCC-3&#8217; and 5&#8217;-GATGCGTTCCGCAACGAACT-3&#8217; for the integrase module with an annealing temperature of 57 &#176;C and an elongation time of 45 s.</li>
		<li>Carry out the PCR reaction in a total volume of 20 &#956;L using the following specific reaction cycle: 5 min initial denaturation at 95 &#176;C, 35 cycles of 30 s at 95 &#176;C, 30 s at the annealing temperature and the elongation step at 72 &#176;C (annealing temperature and elongation time are specific for each primer couple) and a final elongation step of 7 min at 72 &#176;C.</li>
	</ol>
	</li>
	<li>Syringe agroinfiltration
	<ol>
		<li>Inoculate the three A. tumefaciens transformants in 50 mL of LB medium containing 50 &#956;g/mL rifampicin and the following appropriate vector-specific antibiotics: 50 &#956;g/mL carbenicillin for A. tumefaciens transformed with pICH20111, pICH14011 or pICH7410.eGFP, or 50 &#956;g/mL kanamycin for A. tumefaciens transformed with pICH31070. Grow by shaking overnight at 28 &#176;C.</li>
		<li>Pellet overnight bacterial cultures by centrifugation at 4,500 x g for 20 min and resuspend them in 100 mL (or two volumes of the initial bacterial culture) of infiltration buffer containing 10 mM 4-morpholineethanesulfonic acid (MES; pH 5.5) and 10 mM MgSO4, without considering the OD600. Incubate the suspensions at room temperature (RT) for 3 h.</li>
		<li>Mix equal volumes of bacterial suspensions containing one of the three modules, GAD65mut, &#8710;87GAD65mut or eGFP 3&#8217; module, with 5&#8217; module and integrase module. Use the suspension mix for syringe infiltration of red beet and spinach leaves.</li>
		<li>Place 5 mL of the suspension in a syringe without the needle. Press the tip of the syringe against the underside of the leaf for both spinach and red beet plants, and meanwhile apply a gentle counterpressure to the other side of the leaf.</li>
		<li>Infiltrate the first three completely expanded leaves starting from the apex for each plant. Label the agroinfiltrated leaves with a paper tag on the leaf stem. Return the plants in a growth chamber under standard conditions. 
		NOTE: For health and safety reasons, wear eye protection and gloves during infiltration process.</li>
		<li>Collect agroinfiltrated leaves from 4 to 14 days post infection (dpi) and freeze them in liquid nitrogen. Store plant tissue at -80 &#176;C.</li>
	</ol>
	</li>
	<li>Vacuum agroinfiltration
	<ol>
		<li>Grow separately the three A. tumefaciens transformants in 50 mL of LB medium containing 50 &#956;g/mL rifampicin and appropriate vector-specific antibiotic by shaking overnight at 28 &#176;C.</li>
		<li>Pellet overnight bacterial cultures by centrifugation at 4,500 x g for 20 min. Resuspend the pellet in 1 L of infiltration buffer to an OD600 of 0.35 and incubate the suspensions at RT for 3 h.</li>
		<li>Add 0.01% v/v of the detergent (polysorbate 20) to each suspension. Mix equal volumes of bacterial suspensions containing one of the three modules, GAD65mut, &#8710;87GAD65mut or eGFP 3&#8217; module, with 5&#8217; module and integrase module.</li>
		<li>Insert one plant (six-week-old red beet plant, see section 1) in the holder. Invert the holder and place on top of a beaker containing the infiltration bath (2 L) to submerge the leaves in the infiltration suspension. 
		NOTE: Ensure that all the leaves are completely dipped in the bacterial suspension. Raise the level with the addition of extra infiltration suspension if required.</li>
		<li>Transfer the infiltration bath with the submerged plant to the infiltration chamber and close it. Turn on the vacuum pump and open the vacuum intake valve on the infiltration chamber.</li>
		<li>Once the pressure in the infiltration chamber has reduced to 90 mbar, keep the vacuum for 3 min. Release the vacuum for 45 s. Once the infiltration chamber has returned to atmospheric pressure, open the chamber and remove the infiltrated plant from the bacterial bath.</li>
		<li>Return the plants in a growth chamber under standard conditions.</li>
		<li>Collect agroinfiltrated leaves at the maximum expression dpi, depending on the recombinant protein, and freeze them in liquid nitrogen. Store plant tissue at -80 &#176;C.</li>
	</ol>
	</li>
</ol>
3. Recombinant protein expression analysis
<ol>
	<li>Total soluble protein (TSP) extraction
	<ol>
		<li>Grind the syringe or vacuum infiltrated red beet and spinach leaves, collected in steps 2.2.6 and 2.3.8, to fine powder in liquid nitrogen using mortar and pestle. Transfer the powder into 15 mL plastic tubes and store the material at -80 &#176;C.</li>
		<li>Add 900 &#181;L of extraction buffer (50 mM sodium phosphate pH 8.0, 20 mM sodium metabisulphite) to 300 mg of leaf powder. 
		NOTE: The selected ratio between plant tissue weight (mg) to buffer volume (&#181;L) is 1:3.</li>
		<li>Homogenize the mixture by vortexing for 1 min, then centrifuge at 30,000 x g for 40 min at 4 &#176;C.</li>
		<li>Collect the supernatant in a clean tube and store it at -80 &#176;C.</li>
	</ol>
	</li>
	<li>Plant eGFP visualization and quantification
	<ol>
		<li>Load 100 &#181;L of each TSP extract obtained from eGFP expressing leaves, in three technical replicates, on a 96-well plate.</li>
		<li>Put the 96-well plate in a fluorescence reader and start the measurement. Use the 485/535 nm filter set required for eGFP fluorescence detection.</li>
		<li>For the absolute quantification, in the same plate prepare a calibration curve loading different quantities (62.5, 125, 500, 750 and 1,000 ng) of a purified eGFP.</li>
	</ol>
	</li>
	<li>Bicinchoninic acid (BCA) assay for TSP quantification
	<ol>
		<li>Mix 50 parts of Reagent A (Table of Materials) with 1 part of Reagent B (Table of Materials). Prepare sufficient volume of fresh BCA working solution for the samples to be assayed and the calibration standards. 
		NOTE: The volume of BCA working solution required for each sample is 1.9 mL. For the standard procedure with 9 standards (including a blank), 17.1 mL of BCA working solution is required.</li>
		<li>Pipette 0.1 mL of each standard (including a blank), and TSP extracts into a labelled tube. 
		NOTE: As calibration standards, prepare a fresh set of bovine serum albumin (BSA) standards in the 10-1,000 &#956;g/mL range, preferably using the same diluent as samples, such as water. The blank consists of 0.1 mL of the diluent used for calibration standard and sample preparation.</li>
		<li>Add 1.9 mL of BCA working solution and mix thoroughly. Cover the tubes and incubate at 37 &#176;C for 30 min.</li>
		<li>Cool the tubes to RT. Measure the absorbance at 562 nm of all the samples within 10 min. 
		NOTE: Even at RT, the color development continues. No significant error will be introduced if the absorbance measurements of all tubes are done within 10 min.</li>
		<li>Subtract the 562 nm absorbance value of the blank from the readings of the standards and the TSP extracts.</li>
		<li>Plot the blank-corrected 562 nm reading for each standard on its concentration. Determine the protein concentration of each TSP extract.</li>
	</ol>
	</li>
	<li>Perform Coomassie gel staining as previously described in Gecchele et al.8.</li>
	<li>Western blot analysis
	<ol>
		<li>Perform the western blot analysis as previously described in Gecchele et al.8.</li>
		<li>After the electrophoretic separation of proteins, transfer them onto a nitrocellulose membrane using standard techniques. Prepare the blocking solution by mixing 4% milk in phosphate-buffered saline (PBS) pH 7.4. Block the membrane with 10 mL of the blocking solution at RT for 1 h.</li>
		<li>Prepare the rabbit primary antibody at 1:10,000 for the anti-GAD65/67 and anti-LHCB2, and at 1:20,000 for the anti-eGFP in 5 mL of blocking solution with 0.1% detergent. Incubate the membrane with the prepared primary antibody solutions overnight at 4 &#176;C or for 4 h at RT with constant agitation.</li>
		<li>Discard the primary antibody and wash the membrane 3 times for 5 min each with blocking solution containing 0.1% detergent.</li>
		<li>Prepare the horseradish peroxidase (HRP)-conjugate anti-rabbit antibody at 1:10,000 in blocking solution with 0.1% detergent. Incubate the membrane for 1.5 h at RT with constant agitation.</li>
		<li>Discard the secondary antibody and wash the membrane 5 times for 5 min each with PBS-T (PBS supplemented with 0.1% detergent).</li>
		<li>Incubate the membrane with a commercially available luminol solution following the manufacturer&#8217;s instructions. Detect the signal using a chemiluminescence imaging system.</li>
	</ol>
	</li>
</ol>
4. Plant material processing
<ol>
	<li>Harvest the vacuum agroinfiltrated &#8710;87GAD65mut-expressing red beet leaves at the expression peak (11 dpi) and freeze them in liquid nitrogen.</li>
	<li>Lyophilize the frozen leaves for 72 h at -50 &#176;C and 0.04 mbar. Store them at -80 &#176;C.</li>
	<li>Grind the leaves to fine powder and store it at RT in a sealed container with silica gel to exclude the moisture.</li>
</ol>
5. Gastric digestion simulation and cell integrity analysis
<ol>
	<li>Gastric digestion simulation
	<ol>
		<li>Weigh 100 mg of grinded freeze-dried red beet leaves and resuspend it in 6 mL of PBS (pH 7.4).</li>
		<li>Adjust the sample pH to 2 with 6 M HCl.</li>
		<li>Add 4 mg/mL pepsin from porcine gastric mucosa in 10 mM HCl to obtain a final pepsin concentration of 1 mg/mL or a ratio of 1:20 to total soluble proteins. Shake the sample at 37 &#176;C for 120 min.</li>
		<li>Adjust the samples to pH 8 with 1 M NaOH to inactivate the pepsin.</li>
		<li>Centrifuge 750 &#181;L aliquots of each sample at 20,000 x g for 20 min at 4 &#176;C. Collect separately the supernatant and resuspend the pellet in one supernatant volume of loading buffer (1.5 M Tris HCl, pH 6.8, 3% SDS, 15% glycerol, and 4% 2-mercaptoethanol). 
		NOTE: For health and safety reasons, wear gloves and work under fume hood for sample preparation.</li>
		<li>Analyze both the supernatant and the resuspended pellet by western blot analysis8.</li>
	</ol>
	</li>
	<li>Cell integrity analysis
	<ol>
		<li>Prepare two samples of 100 mg of grinded freeze-dried red beet leaves and resuspend both in 6 mL of PBS (pH 7.4).</li>
		<li>Adjust the pH of only one sample to 2 with 6 M HCl. Shake both samples at 37 &#176;C for 120 min.</li>
		<li>Centrifuge 750 &#181;L aliquots of each sample at 20,000 x g for 20 min at 4 &#176;C. Collect separately the supernatant and resuspend the pellet in one supernatant volume of loading buffer.</li>
		<li>Analyze both the supernatant and the resuspended pellet by western blot analysis.</li>
	</ol>
	</li>
</ol>
6. Bioburden assay
<ol>
	<li>Weigh 100 mg of freeze-dried red beet leaves. Resuspend the powder in 8 mL of sterile PBS (pH 7.4) and vortex for 1 min.</li>
	<li>Prepare the LB medium without antibiotics or containing (i) 50 &#181;g/mL rifampicin, (ii) 50 &#181;g/mL each of rifampicin and carbenicillin, (iii) 50 &#181;g/mL each of rifampicin and kanamycin, or (iv) 50 &#181;g/mL each of rifampicin, carbenicillin, and kanamycin.</li>
	<li>Plate 1 mL of each freeze-dried leaf homogenate in one of the 5 selective LB media.</li>
	<li>Incubate all the plates for 3 days at 28 &#176;C.</li>
	<li>Count the Agrobacterium colonies grown on each plate.</li>
	<li>Calculate and define the residual bacterial charge as the number of colony forming units (CFU) per mL of the freeze-dried leaf homogenate (CFU/mL).</li>
</ol>
7. Metabolite extraction
<ol>
	<li>Primary metabolite extraction
	<ol>
		<li>Weigh 30 mg of -80 &#176;C stored, vacuum agroinfiltrated &#8710;87GAD65mut-expressing red beet leaf powder in a 2 mL plastic tube.</li>
		<li>Add 750 &#181;L of cold 70/30 (v/v) methanol/chloroform and vortex for 30 s. Incubate at -20 &#176;C for 2 h. 
		NOTE: All the solvents and additives must be LC-MS grade.</li>
		<li>Add 600 &#181;L of cold water and centrifuge at 17,900 x g at 4 &#176;C for 10 min. Collect and transfer the upper hydroalcoholic phase into a new 2 mL tube. Discard the lower chloroformic phase and the interphase.</li>
		<li>Put the samples into a vacuum concentrator for 3 h to evaporate the solvents.</li>
		<li>Dissolve the pellet obtained from step 7.1.4 in 300 &#181;L of 50/50 (v/v) acetonitrile/water and sonicate the samples for 3 min.</li>
		<li>Pass the solutions through 0.2 &#956;m membrane filters and put them into a transparent fixed 300 &#181;L insert glass tubes.</li>
	</ol>
	</li>
	<li>Secondary metabolite extraction
	<ol>
		<li>Weigh 300 mg of -80 &#176;C stored, vacuum agroinfiltrated &#8710;87GAD65mut-expressing red beet leaf powder in a 15 mL plastic tube.</li>
		<li>Add 3 mL of methanol, vortex for 30 s, and sonicate at 40 kHz for 15 min. 
		NOTE: All the solvents and additives must be LC-MS grade.</li>
		<li>Centrifuge the samples at 4,500 x g at 4 &#176;C for 10 min and transfer the supernatants into new 15 mL tubes.</li>
		<li>Dilute 100 &#181;L of extract 1:3 (v/v) with water and pass the solution through a 0.2 &#956;m membrane filter.</li>
		<li>Put the solution into a transparent fixed 300 &#181;L insert glass tube.</li>
	</ol>
	</li>
	<li>Polar lipid extraction
	<ol>
		<li>Weigh 200 mg of -80 &#176;C stored, vacuum agroinfiltrated &#8710;87GAD65mut-expressing red beet leaf powder in a 15 mL plastic tube.</li>
		<li>Add 200 &#181;L of water and then 2 mL of methanol, and then keep on ice for 1 h. 
		NOTE: All the solvents and additives must be LC-MS grade.</li>
		<li>Vortex for 30 s and sonicate at 40 kHz for 15 min.</li>
		<li>Centrifuge the samples at 4,500 x g at 4 &#176;C for 25 min. Collect and transfer the chloroform phase into 2 mL tubes. Discard the upper hydroalcoholic phase and the interphase.</li>
		<li>Put the samples into a vacuum concentrator for 3 h to evaporate the solvent.</li>
		<li>Dissolve the pellet obtained from step 7.3.5 with 600 &#181;L of methanol.</li>
		<li>Dilute 100 &#181;L of extract 1:5 (v/v) with methanol and pass the solution through a 0.2-&#956;m membrane filter.</li>
		<li>Put the solution into a transparent fixed 300 &#181;L insert glass tube.</li>
	</ol>
	</li>
</ol>
8. Liquid chromatography mass spectrometry analysis and data processing
<ol>
	<li>Set up the LC-MS system as recommended by the supplier. 
	NOTE: The LC section consists of an autosampler coupled with HPLC equipped with a C18 guard column (75 x 2.1 mm, particle size 5 &#181;m) in front of a C18 column (150 x 2.1 mm, particle size 3 &#181;m) for the analysis of secondary metabolites and polar lipids, whereas with a HILIC guard column (7.5 x 2.1 mm, 3 &#181;m) in front of an HILIC column (150 x 2.1 mm, particle size 2.7 &#181;m). The MS is an ion trap mass spectrometer provided with either an electrospray ionization (ESI) or an atmospheric pressure chemical ionisation (APCI) sources.</li>
	<li>Prepare the appropriate solvents for the HPLC gradients. For primary metabolite analysis, use 20 mM ammonium formate as solvent A; 95% acetonitrile, 5% water plus 10 mM ammonium formate as solvent B. For secondary metabolite analysis, use water plus 0.05% formic acid (A) and acetonitrile plus 0.05% formic acid (B). For polar lipid analysis, use water plus 0.05% formic acid (A) and 100% acetonitrile (B). 
	NOTE: The solvents and additives must be LC-MS grade.</li>
	<li>Use the gradients reported in Table 1 for metabolite elution. Set the flow rate at 0.2 mL/min. Inject 10 &#181;L of each sample for both secondary metabolites and polar lipids, whereas inject 5 &#181;L for primary metabolites.</li>
	<li>Prepare a quality control (QC) sample by mixing equal portions of different samples to have a representative mixture of each experimental condition. Analyse the QC sample during the experiment to monitor instrument efficiency. Specifically, insert a QC sample analysis after each 10 sample-batch.</li>
	<li>Randomize the samples to avoid instrument-driven effects.</li>
	<li>After 9 analyses, insert a column cleaning method and a blank analysis immediately after. 
	NOTE: Perform a slow gradient between the two solvents with an isocratic elution at high percentage of the strongest solvent. The blank consists of an injection of a pure methanol: water (50/50, v/v) to improve retention time reproducibility in the following analysis.</li>
	<li>Set up the instrument to acquire mass spectra in alternate positive and negative ionization modes using the parameters listed in Table 2. 
	NOTE: Other parameters depend on the specific platform.</li>
	<li>Perform the next data processing as explained in Dal Santo et al.9.</li>
</ol>

<ol>
	<li>Merlin, M., Pezzotti, M., Avesani, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Edible+plants+for+oral+delivery+of+biopharmaceuticals.">Edible plants for oral delivery of biopharmaceuticals.</a> British Journal of Clinical Pharmacology. 83 (1), 71-81 (2017).</li><li>Merlin, M., Gecchele, E., Capaldi, S., Pezzotti, M., Avesani, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparative+evaluation+of+recombinant+protein+production+in+different+biofactories:+The+green+perspective.">Comparative evaluation of recombinant protein production in different biofactories: The green perspective.</a> BioMed Research International. , (2014).</li><li>Menkhaus, T. J., Bai, Y., Zhang, C., Nikolov, Z. L., Glatz, C. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Considerations+for+the+recovery+of+recombinant+proteins+from+plants.">Considerations for the recovery of recombinant proteins from plants.</a> Biotechnology Progress. 20 (4), 1001-1014 (2004).</li><li>Avesani, L., Bortesi, L., Santi, L., Falorni, A., Pezzotti, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Plant-made+pharmaceuticals+for+the+prevention+and+treatment+of+autoimmune+diseases:+Where+are+we?.">Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: Where are we?.</a> Expert Review of Vaccines. 9 (8), 957 (2010).</li><li>Marillonnet, S., Thoeringer, C., Kandzia, R., Klimyuk, V., Gleba, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Systemic+Agrobacterium+tumefaciens-mediated+transfection+of+viral+replicons+for+efficient+transient+expression+in+plants.">Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants.</a> Nature Biotechnology. 23, (2005).</li><li>Ludvigsson, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Update+on+treatment+of+type+1+diabetes+in+childhood.">Update on treatment of type 1 diabetes in childhood.</a> Current Pediatric Reviews. 1 (2), 118-127 (2013).</li><li>Merlin, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Enhanced+GAD65+production+in+plants+using+the+MagnICON+transient+expression+system:+Optimization+of+upstream+production+and+downstream+processing.">Enhanced GAD65 production in plants using the MagnICON transient expression system: Optimization of upstream production and downstream processing.</a> Biotechnology Journal. 11 (4), 542-553 (2016).</li><li>Gecchele, E., Merlin, M., Brozzetti, A., Falorni, A., Pezzotti, M., Avesani, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+Comparative+Analysis+of+Recombinant+Protein+Expression+in+Different+Biofactories:+Bacteria,+Insect+Cells+and+Plant+Systems.">A Comparative Analysis of Recombinant Protein Expression in Different Biofactories: Bacteria, Insect Cells and Plant Systems.</a> Journal of Visualized Experiments. 23 (97), (2015).</li><li>Dal Santo, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+terroir+concept+interpreted+through+grape+berry+metabolomics+and+transcriptomics.">The terroir concept interpreted through grape berry metabolomics and transcriptomics.</a> Journal of Visualized Experiments. 5 (116), (2016).</li><li>Chen, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Agroinfiltration+as+an+effective+and+scalable+strategy+of+gene+delivery+for+production+of+pharmaceutical+proteins.">Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins.</a> Advanced Techniques in Biology and Medicine. 1 (1), (2013).</li><li>Bertini, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Design+of+a+type-1+diabetes+vaccine+candidate+using+edible+plants+expressing+a+major+autoantigen.">Design of a type-1 diabetes vaccine candidate using edible plants expressing a major autoantigen.</a> Frontiers in Plant Science. 9, (2018).</li><li>Avesani, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Improved+in+planta+expression+of+the+human+islet+autoantigen+glutamic+acid+decarboxylase+(GAD65).">Improved in planta expression of the human islet autoantigen glutamic acid decarboxylase (GAD65).</a> Transgenic Research. 12 (2), 203-212 (2003).</li><li>Sep&#250;lveda-Jim&#233;nez, G., Rueda-Ben&#237;tez, P., Porta, H., Rocha-Sosa, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+red+beet+(Beta+vulgaris)+UDP-glucosyltransferase+gene+induced+by+wounding,+bacterial+infiltration+and+oxidative+stress.">A red beet (Beta vulgaris) UDP-glucosyltransferase gene induced by wounding, bacterial infiltration and oxidative stress.</a> Journal of Experimental Botany. 56, (2005).</li><li>Renukuntla, J., Vadlapudi, A. D., Patel, A., Boddu, S. H. S., Mitra, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Approaches+for+enhancing+oral+bioavailability+of+peptides+and+proteins.">Approaches for enhancing oral bioavailability of peptides and proteins.</a> International Journal of Pharmaceutics. 447, 75-93 (2013).</li><li>. Encapsulation importance in pharmaceutical area, how it is done and issues about herbal extraction Available from: <a target="_blank" href="https://www.researchgate.net/publication/271702091_Encapsulation_importance_in_pharmaceutical_area_how_it_is_done_and_issues_about_herbal_extraction">https://www.researchgate.net/publication/271702091_Encapsulation_importance_in_pharmaceutical_area_how_it_is_done_and_issues_about_herbal_extraction</a> (2015)</li><li>Kamei, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Complexation+hydrogels+for+intestinal+delivery+of+interferon+beta+and+calcitonin.">Complexation hydrogels for intestinal delivery of interferon beta and calcitonin.</a> Journal of Controlled Release. 134, 98-102 (2009).</li><li>Tuesca, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Complexation+hydrogels+for+oral+insulin+delivery:+effects+of+polymer+dosing+on+in+vivo+efficacy.">Complexation hydrogels for oral insulin delivery: effects of polymer dosing on in vivo efficacy.</a> Journal of Pharmaceutical Sciences. 97, 2607-2618 (2008).</li><li>Twyman, R. M., Schillberg, S., Fischer, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Optimizing+the+yield+of+recombinant+pharmaceutical+proteins+in+plants.">Optimizing the yield of recombinant pharmaceutical proteins in plants.</a> Current Pharmaceutical Design. 19, 5486-5494 (2013).</li><li>Dhama, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Plant-based+oral+vaccines+for+human+and+animal+pathogens+&#8211;+a+new+era+of+prophylaxis:+current+and+future+perspectives.">Plant-based oral vaccines for human and animal pathogens &#8211; a new era of prophylaxis: current and future perspectives.</a> Journal of Experimental Biology and Agricultural Sciences. 447, 75-93 (2013).</li><li>Hefferon, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reconceptualizing+cancer+immunotherapy+based+on+plant+production+systems.">Reconceptualizing cancer immunotherapy based on plant production systems.</a> Future science. O3, (2017).</li></ol>

The authors have nothing to disclose.

In this study we showed preliminary analysis for the design of a candidate oral vaccine for autoimmune diabetes. The target protein for this experiment was a mutated form of the human 65 kDa Glutamate Decarboxylase, which production and functionality are easily detectable and measurable12. Its expression in different edible plant tissues was mediated by the vectors5, which mediate a high level of recombinant protein production in a very short time frame. The selection of th...

Since the plant molecular biology revolution in 1980s, plant-based systems for the production of biopharmaceuticals can be considered as an alternative to traditional systems based on microbial and mammalian cells1. Plants display several advantages over traditional platforms, with scalability, cost-effectiveness and safety being the most relevant2. The recombinant product can be purified from transformed plant tissue and then administered, either parenterally or orally and, moreover, transformed edible plant can be used directly for oral delivery. The oral route simultaneously promotes mucosal and systemic immunity, and it eliminates the need for needles and specialized medical personnel. Furthermore, oral delivery eliminates the complex downstream processing, which normally accounts for 80% of the total manufacturing cost of a recombinant protein3. All those advantages can be translated into savings in production, supplies and labor reducing the costs of each dose, making the drug affordable to most of the global population.
Several strategies, both for stable transformation and transient expression, were developed for the production of recombinant proteins in plants. Among them, a high-yield deconstructed plant virus-based expression system (e.g., magnICON) provides superior performance leading high yields of recombinant proteins over relatively short timescales4. Many examples of transient expression using the plant virus-based expression&#160;system in Nicotiana benthamiana plants are reported, being the gold standard production host. However, this model plant is not regarded as an edible species due to the alkaloids and other toxic metabolites that are accumulated in its leaves.
In this work, we describe the comparison between two edible plant systems, red beet (Beta vulgaris cv Moulin Rouge) and spinach (Spinacea oleracea cv Industria), for the expression of two candidate forms of the 65 kDa isoform of glutamic acid decarboxylase (GAD65), carried out by the plant virus-based vectors5. GAD65 is a major autoantigen associated to Type 1 Diabetes (T1D) and it is currently under investigation in human clinical trials to prevent or delay T1D by inducing tolerance6. The production of GAD65 in plants has been extensively studied in model plant species as Nicotiana tabacum and N. benthamiana4,5,6,7. Here, we describe the use of edible plant species for the production of the molecule in tissues that can be meant for a direct oral delivery. From a technical point of view, we studied and selected the system for plant agroinfiltration and the edible plant platform for GAD65 production by evaluating different parameters: the recombinant protein expression levels, the residual microbial charge in plant tissue meant for oral delivery, the resistance of GAD65 to the gastric digestion, and the bioequivalence of the transformed plants with the wild type.

<table><tbody><tr><td>0.2-&amp;mu;m Minisart RC4 membrane filters</td><td>Sartorius-Stedim</td><td>17764</td><td></td></tr><tr><td>2&amp;ndash;mercaptoethanol</td><td>Sigma</td><td>M3148</td><td>Toxic; 4 % to make loading buffer with glycerol, SDS and Tris-HCl</td></tr><tr><td>4-Morpholineethanesulfonic acid (MES)</td><td>Sigma</td><td>M8250</td><td>pH 5.5</td></tr><tr><td>96-well plate</td><td>Sarstedt</td><td>833924</td><td></td></tr><tr><td>Acetic acid</td><td>Sigma</td><td>27221</td><td>Corrosive</td></tr><tr><td>Acetonitrile LC-MS grade</td><td>Sigma</td><td>34967</td><td></td></tr><tr><td>Acetosyringone</td><td>Sigma</td><td>D134406</td><td>Toxic &amp;ndash; 0.1 M stock in DMSO</td></tr><tr><td>Agar Bacteriological Grade</td><td>Applichem</td><td>A0949</td><td>15 g/L to make LB medium (pH 7.5 with NaOH) with Yeast extract, NaCl and Tryptone</td></tr><tr><td>Ammonium formate</td><td>Sigma</td><td>70221</td><td></td></tr><tr><td>Anti-eGFP antibody</td><td>ABCam</td><td>ab290</td><td></td></tr><tr><td>Anti-GAD 65/67 antibody</td><td>Sigma</td><td>G5163</td><td></td></tr><tr><td>Anti-LHCB2 antibody</td><td>Agrisera</td><td>AS01 003</td><td></td></tr><tr><td>Brilliant Blue R-250</td><td>Sigma</td><td>B7920</td><td></td></tr><tr><td>C18 Column</td><td>Grace</td><td>&amp;nbsp;&amp;nbsp; -</td><td>Alltima HP C18 (150 mm x 2.1 mm; 3 &amp;mu;m) Column</td></tr><tr><td>C18 Guard Column</td><td>Grace</td><td>&amp;nbsp;&amp;nbsp; -</td><td>Alltima HP C18 (7.5 mm x 2.1 mm; 5 &amp;mu;m) Guard&amp;nbsp; Column</td></tr><tr><td>CalMag Grower</td><td>Peter Excel</td><td>15-5-15</td><td>Fertilizer</td></tr><tr><td>Carbenicillin disodium</td><td>Duchefa Biochemie</td><td>C0109</td><td>Toxic</td></tr><tr><td>Chemiluminescence imaging system</td><td>BioRad</td><td>1708370</td><td>ChemiDoc Touch Imaging System</td></tr><tr><td>Chloroform</td><td>Sigma</td><td>C2432</td><td></td></tr><tr><td>Detergent</td><td>Sigma</td><td>P5927</td><td>Polysorbate 20</td></tr><tr><td>Fluorescence reader</td><td>Perkin-Elmer</td><td>&amp;nbsp;1420-011</td><td>VICTOR Multilabel Counter</td></tr><tr><td>Formic acid LC-MS grade</td><td>Sigma</td><td>94318</td><td></td></tr><tr><td>Glycerol</td><td>Sigma</td><td>G5516</td><td>15 % to make loading buffer with Tris-HCl, SDS and 2&amp;ndash;mercaptoethanol</td></tr><tr><td>GoTaq G2 polymerase</td><td>Promega</td><td>M7841</td><td></td></tr><tr><td>HCl</td><td>Sigma</td><td>H1758</td><td>Corrosive</td></tr><tr><td>HILIC Column</td><td>Grace</td><td>&amp;nbsp;&amp;nbsp; -</td><td>Ascentis Express HILIC (150 mm x 2.1 mm; particles size 2.7 &amp;mu;m) Column</td></tr><tr><td>HILIC Guard Column</td><td>Grace</td><td>&amp;nbsp;&amp;nbsp; -</td><td>Vision HT HILIC (7.5 mm x 2.1 mm; 3 &amp;mu;m) Guard&amp;nbsp; Column</td></tr><tr><td>Horseradish peroxidase (HRP)-conjugate anti-rabbit antibody</td><td>Sigma</td><td>A6154</td><td>Do not freeze/thaw too many times</td></tr><tr><td>HPLC Autosampler</td><td>Beckman Coulter</td><td>&amp;nbsp;&amp;nbsp; -</td><td>System Gold 508 Autosampler</td></tr><tr><td>HPLC System</td><td>Beckman Coulter</td><td>&amp;nbsp;&amp;nbsp; -</td><td>System Gold 128 Solvent Module HPLC</td></tr><tr><td>Isopropanol</td><td>Sigma</td><td>24137</td><td>Flamable</td></tr><tr><td>Kanamycin sulfate</td><td>Sigma</td><td>K4000</td><td>Toxic</td></tr><tr><td>KCl</td><td>Sigma</td><td>P9541</td><td>2 g/L with NaCl , Na&lt;sub&gt;2&lt;/sub&gt;HPO&lt;sub&gt;4&lt;/sub&gt; and KH&lt;sub&gt;2&lt;/sub&gt;PO&lt;sub&gt;4&lt;/sub&gt; to make PBS</td></tr><tr><td>KH&lt;sub&gt;2&lt;/sub&gt;PO&lt;sub&gt;4&lt;/sub&gt;</td><td>Sigma</td><td>P9791</td><td>2.4 g/L with NaCl , Na&lt;sub&gt;2&lt;/sub&gt;HPO&lt;sub&gt;4&lt;/sub&gt; and KCl to make PBS</td></tr><tr><td>Loading Buffer</td><td></td><td></td><td></td></tr><tr><td>Luminol solution</td><td>Ge Healthcare</td><td>RPN2232</td><td>Prepare the solution using the ECL Prime Western Blotting System commercial kit</td></tr><tr><td>Lyophilizator</td><td>5Pascal</td><td>LIO5P0000DGT</td><td></td></tr><tr><td>Mass Spectometer</td><td>Bruker Daltonics</td><td>&amp;nbsp; -</td><td>Bruker Esquire 6000; the mass spectrometer was equipped with an ESI source and the analyzer was an ion trap</td></tr><tr><td>Methanol</td><td>Sigma</td><td>32213</td><td></td></tr><tr><td>MgSO&lt;sub&gt;4&lt;/sub&gt;</td><td>Sigma</td><td>M7506</td><td></td></tr><tr><td>Milk-blocking solution</td><td>Ristora</td><td>&amp;nbsp;&amp;nbsp; -</td><td>3 % in PBS</td></tr><tr><td>Na&lt;sub&gt;2&lt;/sub&gt;HPO&lt;sub&gt;4&lt;/sub&gt;</td><td>Sigma</td><td>S7907</td><td>Use with NaH&lt;sub&gt;2&lt;/sub&gt;PO&lt;sub&gt;4&lt;/sub&gt; to make Sodium Phospate buffer</td></tr><tr><td>NaCl</td><td>Sigma</td><td>S3014</td><td>80 g/L with KCl, Na2HPO4 and KH2PO4 to make PBS; 10 g/L to make LB medium (pH 7.5 with NaOH) with Yeast extract, Tryptone and Agar Bacteriological Grade</td></tr><tr><td>NaH&lt;sub&gt;2&lt;/sub&gt;PO&lt;sub&gt;4&lt;/sub&gt;</td><td>Sigma</td><td>S8282</td><td>&amp;nbsp;Use with Na&lt;sub&gt;2&lt;/sub&gt;HPO&lt;sub&gt;4&lt;/sub&gt; to make Sodium Phospate buffer; 14.4 g/L to make PBS</td></tr><tr><td>NaOH</td><td>Sigma</td><td>S8045</td><td></td></tr><tr><td>Nitrocellulase membrane</td><td>Ge Healthcare</td><td>10600002</td><td></td></tr><tr><td>Pepsin from porcine gastric mucosa</td><td>Sigma</td><td>P7000</td><td></td></tr><tr><td>Peroxidase substrate ECL</td><td>GE Healthcare</td><td>RPN2235</td><td>Light sensitive material</td></tr><tr><td>Pump Vacuum Press</td><td>VWR</td><td>111400000098</td><td></td></tr><tr><td>Reagent A</td><td>Sigma</td><td>B9643</td><td>Use 50 parts of this reagent with 1 part of reagent B to prepare BCA working solution</td></tr><tr><td>Reagent B</td><td>Sigma</td><td>B9643</td><td>Use 1 part of this reagent with 50 parts of reagent A to prepare BCA working solution</td></tr><tr><td>Rifampicin</td><td>Duchefa Biochemie</td><td>R0146</td><td>Toxic &amp;ndash; 25 mg/mL stock in DMSO</td></tr><tr><td>SDS (Sodium dodecyl sulphate)</td><td>Sigma</td><td>L3771</td><td>Flamable, toxic, corrosive-10 % stock; 3 % to make loading buffer with Tris-HCl, Glycerol and 2&amp;ndash;mercaptoethanol</td></tr><tr><td>Sodium metabisulphite</td><td>Sigma</td><td>7681-57-4</td><td></td></tr><tr><td>Sonicator system</td><td>Soltec</td><td>090.003.0003</td><td>Sonica&amp;reg; 2200 MH; frequency 40 khz</td></tr><tr><td>Syringe</td><td>Terumo</td><td>&amp;nbsp;&amp;nbsp; -</td><td></td></tr><tr><td>Transparent fixed 300-&amp;micro;L insert glass tubes</td><td>Thermo Scientific</td><td>11573680</td><td></td></tr><tr><td>Trizma Base</td><td>Sigma</td><td>T1503</td><td>Adjust pH with 1N HCl to make Tris-HCl buffer, use 1,5M Tris-HCl (pH 6.8) to make loading buffer with SDS, Glycerol and 2&amp;ndash;mercaptoethanol</td></tr><tr><td>Tryptone</td><td>Formedium</td><td>TRP03</td><td>10 g/L to make LB medium (pH 7.5 with NaOH) with Yeast extract, NaCl and Agar Bacteriological Grade</td></tr><tr><td>Vacuum concentrator</td><td>Heto</td><td>3878 F1-3</td><td>Speed-vac System</td></tr><tr><td>Water LC-MS grade</td><td>Sigma</td><td>39253</td><td></td></tr><tr><td>Yeast extract</td><td>Sigma</td><td>Y1333</td><td>5 g/L to make LB medium (pH 7.5 with NaOH) with Tryptone, NaCl and Agar Bacteriological Grade</td></tr></tbody></table>

transient expression in red beet of a biopharmaceutical candidate vaccine for type-1 diabetes

Plant molecular farming is the use of plants to produce molecules of interest. In this perspective, plants may be used both as bioreactors for the production and subsequent purification of the final product and for the direct oral delivery of heterologous proteins when using edible plant species. In this work, we present the development of a candidate oral vaccine against Type 1 Diabetes (T1D) in edible plant systems using deconstructed plant virus-based recombinant DNA technology, delivered with vacuum infiltration. Our results show that a red beet is a suitable host for the transient expression of a human derived autoantigen associated to T1D, considered to be a promising candidate as a T1D vaccine. Leaves producing the autoantigen were thoroughly characterized for their resistance to gastric digestion, for the presence of residual bacterial charge and for their secondary metabolic profile, giving an overview of the process production for the potential use of plants for direct oral delivery of a heterologous protein. Our analysis showed almost complete degradation of the freeze-dried candidate oral vaccine following a simulated gastric digestion, suggesting that an encapsulation strategy in the manufacture of the plant-derived GAD vaccine is required.

In this work, the workflow for the development of an oral vaccine in edible plant tissues is presented. The focus of this work is the expression of a target protein in an edible host plant species and the characterization of the potential oral vaccine.
The first step involved the evaluation of the suitability of the plant virus-based expression technology to produce recombinant proteins in edible plant systems. For this aim, we ...

Watch this Scientific Journal Video about Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes at JoVE.com

Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes

Here, we present a protocol to produce an oral vaccine candidate against Type 1 diabetes in an edible plant.

Plant molecular farming is the use of plants to produce molecules of interest. In this perspective, plants may be used both as bioreactors for the ...

transient-expression-red-beet-biopharmaceutical-candidate-vaccine-for

Research

JoVE Journal

Bioengineering

7.9K Views.  University of Verona. Onder de verschillende strategieën voor de productie van recombinant eiwit in planten, de gedeconstrueerde plantaardige VERS expressie biedt superieure prestaties, wat leidt tot hoge opbrengsten over een relatief kort tijdsbestek. Replicatie van deze technologie voor de productie van een oraal vaccin heeft een groot potentieel om in de nabije toekomst een alternatief te worden voor conventionele vaccins. Lyophilized rode bieten bladeren tijdelijk getransformeerd accumuleert een hoeveelheid f...

Video: Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Precise control of transgene expression is desirable in biological and clinical studies. However, because the binary feature of currently employed gene switches requires the transfer of two therapeutic expression units concurrently into a single cell, the practical application of the system for gene therapy is limited. To simplify the transgene expression system, we generated a gene switch designated as pEUI(+) encompassing a complete set of transgene expression modules in a single vector. Comprising of the GAL4 DNA-binding domain and modified EcR (GvEcR), a minimal VP16 activation domain fused with a GAL4 DNA-binding domain, as well as a modified Drosophila ecdysone receptor (EcR), the newly developed singular gene switch is highly responsive to the administration of a chemical inducer in a time- and dosage-dependent manner. The pEUI(+) vector is a potentially powerful tool for improving the control of transgene expression in both biological research and pre-clinical studies. Here, we present a detailed protocol for modulation of a transient and stable transgene expression using pEUI(+) vector by the treatment of tebufenozide (Teb). Additionally, we share important guidelines for the use of Teb as a chemical inducer.

Here, we present a protocol for the modulation of transgene expression using pEUI(+) singular gene switch by tebufenozide treatment.

Precise control of transgene expression is desirable in biological and clinical studies. However, because the binary feature of currently employed gene ...

Genetics

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Glucose homeostasis is primarily controlled by the endocrine hormones insulin and glucagon, secreted from the pancreatic beta and alpha cells, respectively. Functional beta cell mass is determined by the anatomical beta cell mass as well as the ability of the beta cells to respond to a nutrient load. A loss of functional beta cell mass is central to both major forms of diabetes 1-3. Whereas the declining functional beta cell mass results from an autoimmune attack in type 1 diabetes, in type 2 diabetes, this decrement develops from both an inability of beta cells to secrete insulin appropriately and the destruction of beta cells from a cadre of mechanisms. Thus, efforts to restore functional beta cell mass are paramount to the better treatment of and potential cures for diabetes.
Efforts are underway to identify molecular pathways that can be exploited to stimulate the replication and enhance the function of beta cells. Ideally, therapeutic targets would improve both beta cell growth and function. Perhaps more important though is to identify whether a strategy that stimulates beta cell growth comes at the cost of impairing beta cell function (such as with some oncogenes) and vice versa.
By systematically suppressing or overexpressing the expression of target genes in isolated rat islets, one can identify potential therapeutic targets for increasing functional beta cell mass 4-6. Adenoviral vectors can be employed to efficiently overexpress or knockdown proteins in isolated rat islets 4,7-15. Here, we present a method to manipulate gene expression utilizing adenoviral transduction and assess islet replication and beta cell function in isolated rat islets (Figure 1). This method has been used previously to identify novel targets that modulate beta cell replication or function 5,6,8,9,16,17.

This protocol allows one to identify factors that modulate functional beta cell mass to find potential therapeutic targets for the treatment of diabetes. The protocol consists of a streamlined method to assess islet replication and beta cell function in isolated rat islets following manipulation of gene expression with adenoviruses.

Glucose homeostasis is primarily controlled by the endocrine hormones insulin and glucagon, secreted from the pancreatic beta and alpha cells, ...

Medicine

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Various genetic tools are available to modulate genes in pancreatic islets of rodents to dissect function of islet genes for diabetes research. However, the data obtained from rodent islets are often not fully reproduced in or applicable to human islets due to well-known differences in islet structure and function between the species. Currently, techniques that are available to manipulate gene expression of human islets are very limited. Introduction of transgene into intact islets by adenovirus, plasmid, and oligonucleotides often suffers from low efficiency and high toxicity. Low efficiency is especially problematic in gene downregulation studies in intact islets, which require high efficiency. It has been known that enzymatically-dispersed islet cells reaggregate in culture forming spheroids termed pseudoislets. Size-controlled reaggregation of human islet cells creates pseudoislets that maintain dynamic first phase insulin secretion after prolonged culture and provide a window to efficiently introduce lentiviral short hairpin RNA (shRNA) with low toxicity. Here, a detailed protocol for the creation of human pseudoislets after lentiviral transduction using two commercially available multiwell plates is described. The protocol can be easily performed and allows for efficient downregulation of genes and assessment of dynamism of insulin secretion using human islet cells. Thus, human pseudoislets with lentiviral mediated gene modulation provide a powerful and versatile model to assess gene function within human islet cells.

A protocol to create gene modified human pseudoislets from dispersed human islet cells that are transduced by lentivirus carrying short hairpin RNA (shRNA) is presented. This protocol utilizes readily available enzyme and culture vessels, can be performed easily, and produces genetically modified human pseudoislets suitable for functional and morphological studies.

Various genetic tools are available to modulate genes in pancreatic islets of rodents to dissect function of islet genes for diabetes research. However, ...

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Type 1 diabetes is caused by T cell-mediated autoimmune destruction of insulin-producing cells in the pancreas. Until now insulin replacement is still the major therapy, because islet transplantation has been limited by donor availability and by the need for long-term immunosuppression. Induced islet neogenesis by gene transfer of Neuogenin3 (Ngn3), the islet lineage-defining specific transcription factor and Betacellulin (Btc), an islet growth factor has the potential to cure type 1 diabetes.
Adenoviral vectors (Ads) are highly efficient gene transfer vector; however, early generation Ads have several disadvantages for in vivo use. Helper-dependent Ads (HDAds) are the most advanced Ads that were developed to improve the safety profile of early generation of Ads and to prolong transgene expression1. They lack chronic toxicity because they lack viral coding sequences2-5 and retain only Ad cis elements necessary for vector replication and packaging. This allows cloning of up to 36 kb genes.
In this protocol, we describe the method to generate HDAd-Ngn3 and HDAd-Btc and to deliver these vectors into STZ-induced diabetic mice. Our results show that co-injection of HDAd-Ngn3 and HDAd-Btc induces 'neo islets' in the liver and reverses hyperglycemia in diabetic mice.

We describe hepatic neo-islet formation in STZ (streptozotocin)-induced diabetic mice by gene transfer of Neurogenin3 (Ngn3) and Betacellulin (Btc) using helper-dependent adenoviral vector (HDAd) and the reversal of hyperglycemia. Our method takes advantages of helper-dependent adenoviral vectors with their highly efficient in vivo transduction and the long lasting gene expression.

Type 1 diabetes is caused by T cell-mediated autoimmune destruction of insulin-producing cells in the pancreas. Until now insulin replacement is still the ...

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

The nonobese diabetic (NOD) mouse spontaneously develops autoimmune diabetes after 12 weeks of age and is the most extensively studied animal model of human Type 1 diabetes (T1D). Cell transfer studies in irradiated recipient mice have established that T cells are pivotal in T1D pathogenesis in this model. We describe herein a simple method to rapidly induce T1D by adoptive transfer of purified, primary CD4+ T cells from pre-diabetic NOD mice transgenic for the islet-specific T cell receptor (TCR) BDC2.5 into NOD.SCID recipient mice. The major advantages of this technique are that isolation and adoptive transfer of diabetogenic T cells can be completed within the same day, irradiation of the recipients is not required, and a high incidence of T1D is elicited within 2 weeks after T cell transfer. Thus, studies of pathogenesis and therapeutic interventions in T1D can proceed at a faster rate than with methods that rely on heterogenous T cell populations or clones derived from diabetic NOD mice.

We provide a reproducible method to induce type 1 diabetes (T1D) in mice within two weeks by the adoptive transfer of islet antigen-specific, primary CD4+ T cells.

The nonobese diabetic (NOD) mouse spontaneously develops autoimmune diabetes after 12 weeks of age and is the most extensively studied animal model of ...

Immunology and Infection

Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

The development of biomaterials has significantly increased the potential for targeted drug delivery to a variety of cell and tissue types, including the pancreatic &#946;-cells. In addition, biomaterial particles, hydrogels, and scaffolds also provide a unique opportunity to administer sustained, controllable drug delivery to &#946;-cells in culture and in transplanted tissue models. These technologies allow the study of candidate &#946;-cell proliferation factors using intact islets and a translationally relevant system. Moreover, determining the effectiveness and feasibility of candidate factors for stimulating &#946;-cell proliferation in a culture system is critical before moving forward to in vivo models. Herein, we describe a method to co-culture intact mouse islets with biodegradable compound of interest (COI)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres for the purpose of assessing the effects of sustained in situ release of mitogenic factors on &#946;-cell proliferation. This technique describes in detail how to generate PLGA microspheres containing a desired cargo using commercially available reagents. While the described technique uses recombinant human Connective tissue growth factor (rhCTGF) as an example, a wide variety of COI could readily be used. Additionally, this method utilizes 96-well plates to minimize the amount of reagents necessary to assess &#946;-cell proliferation. This protocol can be readily adapted to use alternative biomaterials and other endocrine cell characteristics such as cell survival and differentiation status.

Here, we present methodology to generate and administer compound of interest-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres to intact mouse islets in culture with subsequent immunofluorescence analysis of &#946;-cell proliferation. This method is suitable for determining the efficacy of candidate &#946;-cell mitogens.

The development of biomaterials has significantly increased the potential for targeted drug delivery to a variety of cell and tissue types, including the ...

An In Ovo Model for Testing Insulin-mimetic Compounds

Elevated blood glucose levels in type 2 diabetes mellitus (T2DM), a complex and multifactorial metabolic disease, are caused by insulin resistance and &#946;-cell failure. Various strategies, including the injection of insulin or the usage of insulin-sensitizing drugs, were pursued to treat T2DM or at least reduce the symptoms. In addition, the application of herbal compounds has attracted increasing attention. Thus, it is necessary to find efficient test systems to identify and characterize insulin-mimetic compounds. Here we developed a modified chick embryo model, which enables testing of synthetic compounds and herbal extracts with insulin-mimetic properties. Using a fluorescence microscopy-based primary screen, which quantifies the translocation of Glucose transporter 4 (Glut4) to the plasma membrane, we were able to identify compounds, mainly herbal extracts, which lead to an increase of intracellular glucose concentrations in adipocytes. However, the efficacy of these substances requires further verification in a living organism. Thus, we used an in-ovo approach to identify their blood glucose-reducing properties. The approval by an ethics committee is not needed since the use of chicken embryos during the first two-thirds of embryonic development is not considered an animal experiment. Here, the application of this model is described in detail.

An In Ovo Model for Testing Insulin-mimetic Compounds

In this study, we describe an in-ovo system as a promising tool to test insulin-mimetic compounds in a living organism. The main advantages include adequate throughput rates and acceptable costs, which enable the identification of phytochemicals with insulin-mimetic properties.

Elevated blood glucose levels in type 2 diabetes mellitus (T2DM), a complex and multifactorial metabolic disease, are caused by insulin resistance and ...

Neuroscience

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Type 1 Diabetes (T1D) is characterized by islet-specific autoimmunity leading to beta cell destruction and absolute loss of insulin production. In the spontaneous non-obese diabetes (NOD) mouse model, insulin is the primary target, and genetic manipulation of these animals to remove a single key insulin epitope prevents disease. Thus, selective elimination of professional antigen presenting cells (APCs) bearing this pathogenic epitope is an approach to inhibit the unwanted insulin-specific autoimmune responses, and likely has greater translational potential.
Chimeric antigen receptors (CARs) can redirect T cells to selectively target disease-causing antigens. This technique is fundamental to recent attempts to use cellular engineering for adoptive cell therapy to treat multiple cancers. In this protocol, we describe an optimized T-cell retrovirus (RV) transduction and in vitro expansion protocol that generates high numbers of functional antigen-specific CD8 CAR-T cells starting from a low number of naive cells. Previously multiple CAR-T cell protocols have been described, but typically with relatively low transduction efficiency and cell viability following transduction. In contrast, our protocol provides up to 90% transduction efficiency, and the cells generated can survive more than two weeks in vivo and significantly delay disease onset following a single infusion. We provide a detailed description of the cell maintenance and transduction protocol, so that the critical steps can be easily followed. The whole procedure from primary cell isolation to CAR expression can be performed within 14 days. The general method may be applied to any mouse disease model in which the target is known. Similarly, the specific application (targeting a pathogenic peptide/MHC class II complex) is applicable to any other autoimmune disease model for which a key complex has been identified.

This article describes a protocol for the generation of antigen-specific CD8 T cells, and their expansion in vitro, with the aim of yielding high numbers of functional T cells for use in vitro and in vivo.

Type 1 Diabetes (T1D) is characterized by islet-specific autoimmunity leading to beta cell destruction and absolute loss of insulin production. In the ...

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Agrobacterium-mediated transient protein production in plants is a promising approach to produce vaccine antigens and therapeutic proteins within a short period of time. However, this technology is only just beginning to be applied to large-scale production as many technological obstacles to scale up are now being overcome. Here, we demonstrate a simple and reproducible method for industrial-scale transient protein production based on vacuum infiltration of Nicotiana plants with Agrobacteria carrying launch vectors. Optimization of Agrobacterium cultivation in AB medium allows direct dilution of the bacterial culture in Milli-Q water, simplifying the infiltration process. Among three tested species of Nicotiana, N. excelsiana (N. benthamiana &#215; N. excelsior) was selected as the most promising host due to the ease of infiltration, high level of reporter protein production, and about two-fold higher biomass production under controlled environmental conditions. Induction of Agrobacterium harboring pBID4-GFP (Tobacco mosaic virus-based) using chemicals such as acetosyringone and monosaccharide had no effect on the protein production level. Infiltrating plant under 50 to 100 mbar for 30 or 60 sec resulted in about 95% infiltration of plant leaf tissues. Infiltration with Agrobacterium laboratory strain GV3101 showed the highest protein production compared to Agrobacteria laboratory strains LBA4404 and C58C1 and wild-type Agrobacteria strains at6, at10, at77 and A4. Co-expression of a viral RNA silencing suppressor, p23 or p19, in N. benthamiana resulted in earlier accumulation and increased production (15-25%) of target protein (influenza virus hemagglutinin).

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Transient protein production in Nicotiana plants based on vacuum infiltration with Agrobacteria carrying launch vectors (Tobacco mosaic virus-based) is a rapid and economic approach to produce vaccine antigens and therapeutic proteins. We simplified the procedure and improved target accumulation by optimizing conditions of bacteria cultivation, selecting host species, and co-introducing RNA silencing suppressors.

Agrobacterium-mediated transient protein production in plants is a promising approach to produce vaccine antigens and therapeutic proteins within a short ...

Biology

A Comparative Analysis of Recombinant Protein Expression in Different Biofactories: Bacteria, Insect Cells and Plant Systems

Plant-based systems are considered a valuable platform for the production of recombinant proteins as a result of their well-documented potential for the flexible, low-cost production of high-quality, bioactive products.
In this study, we compared the expression of a target human recombinant protein in traditional fermenter-based cell cultures (bacterial and insect) with plant-based expression systems, both transient and stable.
For each platform, we described the set-up, optimization and length of the production process, the final product quality and the yields and we evaluated provisional production costs, specific for the selected target recombinant protein.
Overall, our results indicate that bacteria are unsuitable for the production of the target protein due to its accumulation within insoluble inclusion bodies. On the other hand, plant-based systems are versatile platforms that allow the production of the selected protein at lower-costs than Baculovirus/insect cell system. In particular, stable transgenic lines displayed the highest-yield of the final product and transient expressing plants the fastest process development. However, not all recombinant proteins may benefit from plant-based systems but the best production platform should be determined empirically with a case-by-case approach, as described here.

In this study the expression of a target human recombinant protein in different production platforms was compared. We focused on traditional fermenter-based cultures and on plants, describing the set-up of each system and highlighting, on the basis of the reported results, the inherent limits and advantages for each platform.

Plant-based systems are considered a valuable platform for the production of recombinant proteins as a result of their well-documented potential for the ...

Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes

Samenvatting

Meer video's verkennen